Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2008-10-01 (17 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BRESSUIRE (79300), Deux-Sevres
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DE L'EUROPE : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE L'EUROPE is a French company
founded 17 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BRESSUIRE (79300),
this company of category PME
shows in 2024 a net income positive of 137 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE L'EUROPE (SIREN 508135530)
Indicator
2024
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
137 261 €
217 467 €
212 851 €
157 682 €
155 255 €
135 684 €
159 675 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE DE L'EUROPE generates positive net income of 137 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 160 k€ -> 137 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
137 261 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.527%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
86.829%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE L'EUROPE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2024
Debt ratio
76.25
56.156
39.4
27.518
15.215
6.132
0.527
Financial autonomy
49.468
56.199
62.701
68.351
74.135
79.996
86.829
Repayment capacity
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
0.532024
2021
2022
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Excellent
In 2024, the debt ratio of SELARL PHARMACIE DE L'EUROPE (0.53) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
86.83%2024
2021
2022
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+12 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE DE L'EUROPE (86.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 272.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
272.677
Liquidity indicators evolution SELARL PHARMACIE DE L'EUROPE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2024
Liquidity ratio
174.575
176.764
181.486
188.183
188.854
205.705
272.677
Interest coverage
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
272.682024
2021
2022
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Excellent+26 pts over 3 years
In 2024, the liquidity ratio of SELARL PHARMACIE DE L'EUROPE (272.68) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of SELARL PHARMACIE DE L'EUROPE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE DE L'EUROPE is estimated at
1 916 265 €
(range 1 334 456€ - 2 866 842€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1334k€1916k€2866k€
1 916 265 €Range: 1 334 456€ - 2 866 842€
NAF 5 année 2024
Valuation method used
Net Income Multiple
137 261 €
×
14.0x
=1 916 265 €
Range: 1 334 457€ - 2 866 842€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE L'EUROPE with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE L'EUROPE
What is the revenue of SELARL PHARMACIE DE L'EUROPE ?
The revenue of SELARL PHARMACIE DE L'EUROPE is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE DE L'EUROPE profitable?
Yes, SELARL PHARMACIE DE L'EUROPE generated a net profit of 137 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE DE L'EUROPE ?
The headquarters of SELARL PHARMACIE DE L'EUROPE is located in BRESSUIRE (79300), in the department Deux-Sevres.
Where to find the tax return of SELARL PHARMACIE DE L'EUROPE ?
The tax return of SELARL PHARMACIE DE L'EUROPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE L'EUROPE operate?
SELARL PHARMACIE DE L'EUROPE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart